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Identity 
Other names: ABP; MGC126834; MGC138391; SBP; 
TEBG 
HGNC (Hugo): SHBG 
Location: 17p13.1 
Note 
This gene encodes a steroid binding protein that was
first described as a plasma protein secreted by the liver; 
lately, it was recognized to be produced also by testis 
germ cells; the protein is now thought to participate in 
the regulation of steroid responses at cell level. The 
encoded protein in biological fluids is a dimer formed 
from identical or nearly identical monomers; in each 
monomer one steroid binding pocket has been 
recognized. SHBG binds androgen and estradiol with 
different affinity. Alternate promoters and several 
spliced transcripts were reported. 
DNA/RNA 
Description 
The human SHBG gene is located on the short arm of 
chromosome 17 (17pter-p12) and consists of eight 
exons. 
Transcription 
Two major SHBG transcripts are known, each 
originating from a different promoter. The variant 1, 
which has also been referred to as SHBG-L, encodes 
the longest protein (isoform 1), while the variant 2 uses 
an alternate in-frame splice site in the 3' coding re ion 
compared to variant 1. These two transcripts differ in 




402 amino acids; 43779 Da each subunit: homodimer. 
Description 
SHBG is a homodimer; each monomer is constituted of 
402 aa, molecular weight 43,7 kDa. The protein 
consists of a signal peptide (1-29 aa) and 2 laminin G-
like domains (domain 1: 45-217 aa; domain 2: 224-390 
aa). Each SHBG monomer has an O-linked 
oligosaccharide at Thr(36) and up to two N-linked 
oligosaccharides at Asn(380) and Asn(396). 
 
 
Schematic representation of SHBG gene. Exons are represented by the blue boxes. 
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Linear structure of SHBG protein. Location of glycosylation sites is shown by red lines. 
 
Localisation 
SHBG is secreted by liver into the blood stream andit 
is synthesized by testis germ cells; it also recognizes a 
specific binding site located on membranes of sex 
steroid target cells (e.g. breast, prostate). 
Function 
SHBG binds and carries sex steroids, regulating their 
biological active fraction; it also regulates sex steroid 
effects in target cells by direct action. 
Homology 
Protein S, Gas6, laminin, agrin. 
Mutations 
Note 
CCG-CTG; Pro-Leu156; reported in 
hyperandrogenism. 
GAC-AAC; Asp-Asn327; reported in estrogen-
dependent breast cancer. 
(TAAAA) n promoter, n=6-11; n>8; reported in: 
polycystic ovary syndrome; CAD in postmenopausal 





Human serum sex hormone-binding globulin (SHBG) 
regulates the bioavailable fraction of circulating 
estradiol that is known to be a critical factor in breast 
cancer. In a case-controlled study within the European 
Prospective Investigation into Cancer and Nutrition 
(EPIC), SHBG levels in postmenopausal women who 
developed breast cancer were confirmed to be 
significantly lower compared with controls, while no 
significant difference was observed in premenopausal 
women. 
SHBG has a direct effect in breast cancer cells; it 
interacts with membranes of these cells, initiates  
 
subsequently a specific intracellular pathway leading to  
cross-talk with the estradiol-activated pathway, finally 
inhibiting several effects of estradiol in breast can er 
cells, e.g. cell proliferation. 
The Asp327Asn polymorphism of SHBG gene is 
related to breast cancer risk. Cui et al. observed a 
significant association of the Asp327Asn 
polymorphism with reduced breast cancer risk and 
Becchis et al. reported a significantly higher frequ ncy 
of the polymorphism in postmenopausal patients with 
ER-positive breast cancer than in ER-negative; more 
recently Costantino and co-workers suggested a 
protective role of this polymorphism since mutated 
SHBG is more effective than wild type protein in 
inhibiting estradiol-induced cell proliferation and anti-
apoptosis, and this is due to the fact that D327N SHBG 




Patients with prostate cancer showed lower SHBG 
levels than benign prostate hypertrophy patients and
controls. 
Alternative splicing of SHBG gene is more pronounced 
in LNCaP and MCF-7 cancer cell lines; at least six 
independent transcripts each, resulting from alternative 
splicing of exons 4, 5, 6, and/or 7 were described.  
SHBG might be a significant multivariate predictor of 
lymph node invasion in patients with prostate cancer. 
The use of preoperative serum SHBG could help to 
identify patients at risk of lymph node invasion. 
Type 2 diabetes mellitus 
Note 
Epidemiological studies consistently show that 
circulating SHBG levels are lower in type 2 diabetes 
patients than in non-diabetic individuals.  
Low circulating levels of SHBG are a strong predictor 
of the risk of type 2 diabetes in women and men.  
Carriers of a variant allele of the SHBG single-
nucleotide polymorphism (SNP) rs6259 and carriers of  
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a rs6257 variant were associated with a risk of type 2 
diabetes following their associated sex hormone-
binding globulin levels. 
Insulin resistance and polycystic ovary 
syndrome (PCOS) 
Note 
SHBG concentrations are inversely associated with 
insulin resistance, and in turn, with the risk of type 2 
diabetes.  
Women with polycystic ovary syndrome (PCOS) 
present low SHBG levels that are negatively correlated 
with body mass index and waist to hip ratio, and are, 
furthermore, associated with insulin resistance. 
Breakpoints 
Note 
An X;17 translocation breakpoint was characterized in 
a 5-year-old female with hypomelanosis of Ito (HI) 
who exhibits characteristic hypopigmented lesions, 
psychomotor retardation, and choroid plexus 
papilloma. A chromosome-17-specific DNA fragment 
was isolated and used to identify cosmid clones 
crossing the translocation from chromosome 17p13. 
Exon trapping identified two known genes from 
chromosome 17: FMR1L2 (the fragile X mental 
retardation syndrome like protein 2) and SHBG (human 
sex hormone-binding globulin). Mapping the FMR1L2 
and SHBG genes showed that neither gene was 
disrupted by the translocation. 
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